Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01: 05 allele in scleroderma patients with interstitial lung disease

Rheumatology (United Kingdom)

Volumn 51, Issue 10, 2012, Pages 1765-1774

  Odani, Toshio ^a   Yasuda, Shinsuke ^a   Ota, Yuko ^a   Fujieda, Yuichiro ^a   Kon, Yujiro ^a   Horita, Tetsuya ^a   Kawaguchi, Yasushi ^a   Atsumi, Tatsuya ^a   Yamanaka, Hisashi ^a   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene expression; Human leucocyte antigen; Microarray; Peripheral blood mononuclear cells; Pulmonary fibrosis; Risk factor; SSC

Indexed keywords

CYCLOSPORIN A; GENOMIC DNA; HLA DRB1 ANTIGEN; HLA DRB5 ANTIGEN; PREDNISOLONE; PROSTAGLANDIN; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC RISK; GENETIC TRANSCRIPTION; GENOTYPING TECHNIQUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCLERODERMA; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; FEMALE; GENOTYPE; HLA-DRB5 CHAINS; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TISSUE ARRAY ANALYSIS; UP-REGULATION;

EID: 84867120210     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes149     Document Type: Article

References (33)

1. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
2. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease fac tors at first visit. Arthritis Rheum 1999;42:2660-5.
3. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
4. Assassi S, Del Junco D, Sutter Ket al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 2009;61:1403-11.
5. Silver RM. Scleroderma: clinical problems: the lungs. Rheum Dis Clin North Am 1996;22:825-40.
6. Highland KB, Silver RM. New developments in sclero derma interstitial lung disease. CurrOpin Rheumatol 2005; 17:737-45.
7. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66: 940-4.
8. Bouros D, Wells AU, Nicholson AG et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6.
9. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39:269-77.
10. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
11. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
12. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-con trolled trial of corticosteroids and intravenous cyclophos phamide followed by oral azathioprine for the treatment ofpulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962-70.
13. Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 2009;21:636-41.
14. Asano Y. Future treatments in systemic sclerosis. J Dermatol 2010;37:54-70.
15. Agarwal SK, Tan FK, Arnett FC. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008;34:17-40, v.
16. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
17. Delgado-Vega A, Sanchez E, Lofgren S, Castillejo-Lopez C, Alarcon-Riquelme ME. Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol 2010;22:698-705.
18. Livak KJ, Schmittgen TD. Analysis of relative gene ex pression data using real-time quantitative PCR and the 2~AACT method. Methods 2001;25:402-8.
19. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
20. Bohgaki T, Atsumi T, Bohgaki M et al. Immunological re-constitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: rela tionship between clinical benefits and intensity of im-munosuppression. J Rheumatol 2009;36:1240-8.
21. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
23. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
24. Olerup O, Zetterquist H. HLA-DRB1*01 subtyping by allele-specific PCR amplification: a sensitive, specific and rapid technique. Tissue Antigens 1991;37:197-204.
25. Olerup O, Zetterquist H. HLA-DR typing by PCR amplifi cation with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-35.
26. Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
27. Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010;42:426-9.
28. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995;12:107-28.
29. Kuwana M, Kaburaki J, Okano Y, Inoko H, Tsuji K. The HLA-DR and DQ genes control theautoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest 1993;92: 1296-301.
30. Briggs DC, Vaughan RW, Welsh KI et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338:661-2.
31. Hashimoto M, Kinoshita T, Yamasaki M et al. Gene fre quencies and haplotypic associations within the HLAregion in 916 unrelated Japanese individuals. Tissue Antigens 1994;44:166-73.
32. Fukazawa T, Kikuchi S, Sasaki H et al. Genomic HLA profiles of MS in Hokkaido, Japan: important role of DPB1*0501 allele. J Neurol 2000;247:175-8.
33. Caillier SJ, Briggs F, Cree BA et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol 2008; 181:5473-80.